<DOC>
	<DOCNO>NCT02385136</DOCNO>
	<brief_summary>The purpose study evaluate safety profile efficacy whole brain radiotherapy ( WBRT ) concomitantly temozolomide ( TMZ ) patient brain metastasis ( BM ) .Patients BM randomly assign 30 Gy WBRT without concomitant TMZ ( 75 mg/m2/d ) plus two cycle TMZ ( 200 mg/m2/d 5 day ) .</brief_summary>
	<brief_title>Temozolomide Concomitant Whole Brain Radiotherapy NSCLC Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>histologically diagnose NSCLC , stage IVb [ ( American Joint Cancer Committee ( AJCC ) , 2002 ) ] , Brain metastasis history hypertension diabetes . brain tumor diameter &gt; 5cm ; RPA class =3 ; pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Radiotherpy</keyword>
	<keyword>Temozolomide</keyword>
</DOC>